Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BLRX 
BioLineRx Ltd (BLRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BLRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $26
1 Year Target Price $26
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 23.62% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.13M USD | Price to earnings Ratio - | 1Y Target Price 26 |
Price to earnings Ratio - | 1Y Target Price 26 | ||
Volume (30-day avg) 2 | Beta 0.88 | 52 Weeks Range 2.30 - 26.80 | Updated Date 08/29/2025 |
52 Weeks Range 2.30 - 26.80 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.08 | Actual - |
Profitability
Profit Margin -45.34% | Operating Margin (TTM) -757.57% |
Management Effectiveness
Return on Assets (TTM) -15.36% | Return on Equity (TTM) -45.94% |
Valuation
Trailing PE - | Forward PE 93.46 | Enterprise Value 467841 | Price to Sales(TTM) 0.94 |
Enterprise Value 467841 | Price to Sales(TTM) 0.94 | ||
Enterprise Value to Revenue 0.03 | Enterprise Value to EBITDA 0.24 | Shares Outstanding 4262680 | Shares Floating 2450907651 |
Shares Outstanding 4262680 | Shares Floating 2450907651 | ||
Percent Insiders 4.08 | Percent Institutions 1.55 |
Upturn AI SWOT
BioLineRx Ltd
Company Overview
History and Background
BioLineRx Ltd. was founded in 2003 and is a clinical-stage biopharmaceutical company focused on oncology. It develops and commercializes novel therapeutics. The company has evolved through strategic partnerships and product acquisitions to build its pipeline.
Core Business Areas
- Oncology: Development and commercialization of therapeutics in the field of oncology, with a focus on hematological malignancies.
Leadership and Structure
The leadership team includes executives with experience in biopharmaceutical development and commercialization. The company structure is organized around research, clinical development, and commercial operations.
Top Products and Market Share
Key Offerings
- Motixafortide (Aphexda): A CXCR4 inhibitor approved for stem cell mobilization in multiple myeloma patients. It competes with G-CSF based products like Neupogen (AMGN). Market share information isn't publicly available.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. The oncology segment is a significant driver of growth.
Positioning
BioLineRx is positioned as a specialty pharmaceutical company focusing on niche oncology markets. Its competitive advantage lies in the differentiated mechanism of action of its lead product.
Total Addressable Market (TAM)
The TAM for stem cell mobilization in multiple myeloma is estimated in the billions of dollars. BioLineRx aims to capture a significant share of this market with Motixafortide.
Upturn SWOT Analysis
Strengths
- FDA-approved product (Aphexda)
- Novel mechanism of action
- Experienced management team
Weaknesses
- Limited commercial infrastructure
- Dependence on a single product
- Limited financial resources
Opportunities
- Expansion of Motixafortide to other indications
- Strategic partnerships and collaborations
- Acquisition of new assets
Threats
- Competition from established therapies
- Regulatory hurdles
- Pricing pressures
Competitors and Market Share
Key Competitors
- AMGN
- SANOY
Competitive Landscape
BioLineRx competes with established pharmaceutical companies in the oncology space. Its competitive advantage lies in its novel therapeutic approach, but it faces challenges related to commercialization and market access.
Growth Trajectory and Initiatives
Historical Growth: BioLineRx's historical growth has been driven by clinical development milestones and regulatory approvals.
Future Projections: Future growth is dependent on the successful commercialization of Motixafortide and pipeline expansion.
Recent Initiatives: Recent initiatives include securing regulatory approval for Motixafortide and building its commercial infrastructure.
Summary
BioLineRx, although currently a micro-cap with limited financials publicly available, has an FDA-approved product, providing revenue and opportunity for future growth in the stem cell mobilization sector. Challenges include commercializing the product in a highly competitive landscape, obtaining favorable reimbursement coverage and limited financial resources for sales and marketing. Successful market penetration and potential pipeline expansion will be crucial for achieving sustained profitability. Close monitoring of its operational expenses, cash flow and competition is essential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioLineRx Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2011-07-25 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://www.biolinerx.com |
Full time employees 28 | Website https://www.biolinerx.com | ||
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.